These products aid in treating several conditions, but are insurers paying for them? Find out.
Innovative PBM performance-based pharmacy networks focus on reducing costs and Improving clinical outcomes
In response to the lack of transparency, health organizations are creating drug pricing tools that deliver patient-specific pricing. Here’s how they work.
A 51-year-old female patient has been taking Forteo (teriparatide) for osteoporosis for the past year. Her insurance company notifies her that the drug is no longer on its formulary.
Prices of more than 20% of generic drugs increased more than 100% between 2010 and 2015.
Legislation removes FDA involvement when patients seek experimental medications. Here’s what critics and proponents say.
Two health plans are sharing the wealth—in this case, drug discounts from manufacturers—with consumers at point of sale.
Experts weigh in on the spending outlook for these high-cost conditions.
Gene therapy is leaving its mark, while payers contemplate payment models, value, and efficacy issues.
A lack of national standards and less than optimal oversight of many inpatient, opioid addiction rehabilitation programs is raising questions about the level of services, personnel, and quality of care many patients are receiving.